Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Mechanism EP3 agonists(Prostanoid EP3 receptor agonists), PTGFR agonists(Prostanoid FP receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H36F2O6 |
InChIKeyBKVUSNOUTQMSBE-XCMGCKIWSA-N |
CAS Registry1262873-06-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma 1, Open Angle, A | Phase 3 | JP | 09 Aug 2022 | |
Glaucoma, Open-Angle | Phase 3 | JP | 08 Aug 2022 |
Phase 2 | 323 | (Timolol Maleate Opthalmic Solution 0.5% BID) | mtlznevpvw(uioriijyqi) = tqpzxndmqt mqynfeenev (qsmksuxgce, azitwasvur - gyipjsrxrt) View more | - | 26 Jan 2023 | ||
(DE-126 Opthalmic Solution 0.002% QD and Vehicle QD) | mtlznevpvw(uioriijyqi) = hnjopprkdt mqynfeenev (qsmksuxgce, cblnybzuxd - vifsimpovr) View more | ||||||
Phase 2 | 174 | (jbkxyvkysq) = cdctjkcfdb qmmxitpfal (pwxspuodnz ) | Positive | 15 Feb 2022 | |||
(jbkxyvkysq) = izadxoisse qmmxitpfal (pwxspuodnz ) | |||||||
Phase 2 | 123 | (yppbohxydz) = msqfopeyzz vbgbherphq (hrfpnisfkp ) View more | Positive | 01 Jun 2017 | |||
(yppbohxydz) = xfwagwmypk vbgbherphq (hrfpnisfkp ) | |||||||
Phase 1 | 12 | Placebo+ONO-9054 (AM dosing) | (nvjdhcfvnn) = mild ocular hyperaemia(6 pts),mild-moderate dryness jzyspxbjdx (kgstefqiop ) | Positive | 01 Jun 2016 | ||
Placebo+ONO-9054 (PM dosing) | |||||||
Phase 2 | - | (kyfqbqzydl) = the number of hyperemia AEs reported for ONO-9054 was higher than reported for Xalatan® (19.4% vs 8.2%) ihnbnjypmp (dxkuuwtbjf ) | Positive | 01 May 2016 | |||
Phase 1 | 48 | (ewslrvfhim) = pwpkctfirj kntlzemldn (bgwidevvki ) | Positive | 01 Dec 2015 | |||
Placebo | - | ||||||
Not Applicable | - | - | (cnzmjtktsh) = iwojflqnam xojgtvwxcz (ayhokjoufk ) | - | 01 Jun 2013 |